UNSPSC 51371805: Ketobemidone hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C15H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U9U6LTV80K, chemically known as 1-propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride but more generally known as ketobemidone hydrochloride, which bears US NIH Compound Identifier 80069. European Medicines Agency schedules Ketobemidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02832MIG.

UNSPSC 51371805 Ketobemidone hydrochloride is a Commodity code that captures state and local procurement of prescription pharmaceuticals and related health products, though recent solicitations tagged under this code reflect a broader pharmaceutical-supply ecosystem encompassing naloxone, generic multi-source drugs, and OTC products rather than ketobemidone specifically. State and local issuing bodies purchasing under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Work being solicited ranges from direct procurement of specific pharmaceutical units (such as naloxone and drug deactivation systems for community health programs) to framework agreements with manufacturers and wholesalers supplying generic pharmaceuticals and OTC products to state and local facilities across multiple participating jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a bid deadline of July 26, 2023 and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state interest in direct contracting models outside traditional pharmacy benefit manager and wholesale channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with proposals due March 26, 2026 and contract effectiveness July 1, 2026; pricing evaluation weighted 75 percent on competitiveness, with vendors required to certify cGMP and Drug Supply Chain Security Act compliance and maintain $5,000,000 commercial general liability coverage.